Merck & Co., Inc. (NYSE:MRK) Shares Sold by First National Bank of Mount Dora Trust Investment Services

First National Bank of Mount Dora Trust Investment Services lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 1.5% in the second quarter, Holdings Channel reports. The firm owned 49,231 shares of the company’s stock after selling 761 shares during the period. Merck & Co., Inc. accounts for 1.5% of First National Bank of Mount Dora Trust Investment Services’ investment portfolio, making the stock its 25th biggest position. First National Bank of Mount Dora Trust Investment Services’ holdings in Merck & Co., Inc. were worth $4,488,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MRK. Joseph P. Lucia & Associates LLC acquired a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $25,000. Landmark Wealth Management LLC acquired a new stake in Merck & Co., Inc. during the 1st quarter worth approximately $25,000. Front Row Advisors LLC increased its position in Merck & Co., Inc. by 89.4% during the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after purchasing an additional 160 shares in the last quarter. Okabena Investment Services Inc. acquired a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $27,000. Finally, Western Pacific Wealth Management LP acquired a new stake in Merck & Co., Inc. in the fourth quarter valued at approximately $29,000. Institutional investors and hedge funds own 73.33% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of MRK opened at $87.51 on Friday. The business’s fifty day moving average price is $88.83 and its 200 day moving average price is $87.81. Merck & Co., Inc. has a 12-month low of $71.50 and a 12-month high of $95.72. The stock has a market capitalization of $221.69 billion, a PE ratio of 13.40, a price-to-earnings-growth ratio of 1.14 and a beta of 0.33. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.39 and a quick ratio of 1.15.

Merck & Co., Inc. (NYSE:MRKGet Rating) last announced its quarterly earnings data on Thursday, July 28th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.20. Merck & Co., Inc. had a return on equity of 48.45% and a net margin of 29.00%. The firm had revenue of $14.59 billion for the quarter, compared to analysts’ expectations of $13.85 billion. During the same period last year, the business posted $1.31 earnings per share. The firm’s revenue for the quarter was up 28.0% on a year-over-year basis. Equities research analysts forecast that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be given a $0.69 dividend. This represents a $2.76 annualized dividend and a yield of 3.15%. The ex-dividend date of this dividend is Wednesday, September 14th. Merck & Co., Inc.’s dividend payout ratio is presently 42.27%.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Morgan Stanley increased their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. Daiwa Capital Markets raised shares of Merck & Co., Inc. from a “neutral” rating to a “buy” rating and increased their price objective for the company from $89.00 to $102.00 in a research report on Wednesday, July 6th. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Cowen increased their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Finally, Mizuho assumed coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They issued a “buy” rating and a $100.00 price objective for the company. Seven analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and an average target price of $98.28.

Merck & Co., Inc. Profile

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.